Managing Immunotherapy Related Organ Toxicities


Book Description

Certain organ toxicities can be severe and life-threatening. Therefore, it is crucial to recognize these disease entities early on to provide prompt and effective treatments to improve the quality of patient care, and enable the continuation of cancer therapy long-term. A clinical handbook with a particular focus in this field is lacking. This handbook focuses on the comprehensive, systematic review of clinical aspects of immunotherapy-induced toxicities in 15 major organ systems. The organs covered include endocrine, eye, gut, heart, kidney, liver, lung, muscular-skeletal, neuro, pancreas and skin etc. A unique feature about this book is the inclusion of perspectives from Anesthesiology, Infectious Disease, and Pathology besides specific organ toxicity management. The contributors are a group of experts offering routine clinical care to patients with most complex and refractory toxicity conditions, conducting pioneering research, and providing the guidance for the clinical practice to the peers and trainees in the field. The topics of each chapter include incidence, clinical presentations, evaluation, management, and long term follow up of each disease entity. There is also a simplified management algorithm or table illustrated in each chapter as well as audio PowerPoint slide deck to provide straightforward general instruction on the evaluation and treatment.




SITC’s Guide to Managing Immunotherapy Toxicity


Book Description

The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer




Drug-Induced Liver Injury


Book Description

Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series




Handbook of Cancer Treatment-Related Symptoms and Toxicities E-Book


Book Description

Early recognition and management of adverse effects of cancer treatments are essential for optimal care of patients with cancer, and drastically different approaches are required for different physiologic reactions. Handbook of Cancer Treatment-Related Symptoms and Toxicities is a focused, one-stop resource that enables clinicians to quickly find up-to-date, reliable information needed at the point of care. The high-yield approach prioritizes the most common toxicities associated with cancer treatment, and concise, templated chapters offer fast access to information needed in day-to-day practice. - Presents a user-friendly overview of cancer treatment-related symptoms and toxicities management in a practical, easy-to-use format, allowing you to quickly find information in one convenient, concise resource. - Covers systemic and radiation therapies, including chemotherapy, immunotherapy, targeted therapies, and radiation therapy, detailing symptoms of each toxicity to confirm your diagnosis. - Overviews pharmacologic and non-pharmacologic approaches to symptom management. - Offers recommendations for mitigating toxicities in high-risk patients. - Discusses key topics such as management of infusion reactions, when the need for biopsy is warranted, and the unique challenges posed by novel immunotherapies.




Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book


Book Description

From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.




Immune Checkpoint Inhibitors in Cancer


Book Description

Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It's an ideal concise reference for trainee and practicing medical oncologists, as well as those in research. - Discusses the current understanding of how to best harness the immune system against different types of cancer at various stages. - Helps you translate current research and literature into practical information for daily practice. - Presents information logically organized by disease site. - Covers tumor immunology and biology; toxicities associated with immune checkpoint inhibitors; and future outlooks. - Consolidates today's available information on this timely topic into one convenient resource.




Hepatotoxicity


Book Description

Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury.




Cancer Immunotherapy Principles and Practice


Book Description

Part 1: Intratumoral Signatures Associated With Immune Responsiveness




Radiobiology Self-Assessment Guide


Book Description

Radiobiology Self-Assessment Guide--a companion to the Radiation Oncology Self-Assessment Guide and Physics in Radiation Oncology Self-Assessment Guide--is a comprehensive review for practitioners of radiation oncology looking to enhance their knowledge of radiobiology. It covers in depth the principles of radiobiology as applied to radiation oncology along with their clinical applications. To foster retention of key concepts and data, the resource utilizes a user-friendly "flash card" question and answer format with over 700 questions. The questions are supported by detailed answers and rationales along with reference citations for source information. The guide is comprised of 29 chapters and cover topics commonly found on the radiation and cancer biology portion of the radiation oncology board examination. Aspects of basic radiobiology covered include fundamentals such as cell cycle, cell survival curves and interactions of radiation with matter, and acute and long-term sequelae of radiation. Modern concepts such as immunotherapy, radiogenomics, and normal and cancer stem cells are also included. Focused and authoritative, this must-have review provides the expertise of faculty from the Department of Radiation Oncology at the Cleveland Clinic Taussig Cancer Institute and Lerner Research Institute. Key Features: Provides a comprehensive study guide for the Radiation and Cancer Biology portion to the Radiation Oncology Board Exam Includes more than 700 questions with detailed answers and rationales on flip pages for easy, flash card-like review Includes essential review of cancer biology concepts such as immunotherapy, stem cells, gene therapy, chemotherapy and targeted agents Content provided by a vast array of contributors, including attending radiation oncology physicians, physicists, and radiation oncology residents




Immunotherapy of Hepatocellular Carcinoma


Book Description

In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.